Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
The Angeles Clinic and Research Institute - California, Los Angeles, California UC San Diego Health System - La Jolla, San Diego, California Yale Cancer Center - New Heaven, New Haven, Connecticut Sarah Cannon Research Institute (SCRI) - Nashville, Nashville, Tennessee Virginia Cancer Specialist, Fairfax, Virginia France
Centre Léon Bérard - Lyon, Lyon Institut de Cancerologie de l'Ouest (St-Herblain), Saint-Herblain Spain
Barcelona - Val D'Hebron, Barcelona Fundacion Jimenez Diaz - Madrid, Madrid M.D. Anderson Cancer Center Madrid, Madrid